[From bench to bedside: experience of the glioblastoma model for the optimization of radiosensitization].
Despite significant progress in the treatment of glioblastoma, the prognosis of these radioresistant, invasive and hypoxic tumours remain dark. The constant relapse after treatment of this tumour is in part due to its intra-cellular but also micro-environmental radioresistance, largely controlled by growth factors and their receptors. The complexity of the biology of these tumours and the presence of numerous cross-talks between the pathways of these different growth factors can be in part responsible for the negative results obtained in clinical trials associating radiotherapy and targeted drugs designed without previous in vitro and in vivo studies validating the proof of concept of a specific target as key factor of radioresistance. In the aim to optimize the treatment of glioblastoma and to reduce the risks of failure of new trials, several laboratories and clinical departments are developing translational research in radiotherapy and radiobiology, validating in vitro and then in orthotopic xenografts interesting targets, then studying the radiosensitizing effect of targeted drugs directed against these proteins, studying the mechanisms of action and resistance of these drugs, validating these proteins as predictive factors of response to radiotherapy in the patients, and then designing clinical trials, integrating metabolic or functional imaging and surrogate markers to better understand the mechanism of action of these associations. We describe in this article the main translational research axis developed for radiosensitizing glioblastoma, which our lab and department have pursued for several years.
Département des radiations, institut Claudius-Regaud, 20-24, rue du Pont-Saint-Pierre, 31052 Toulouse cedex 3, France. moyal.elizabeth@claudiusregaud.fr
E
E
Cohen-Jonathan Moyal
D016543:Central Nervous System Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D005909:Glioblastoma / Q000378:metabolism / Q000532:radiotherapy*; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism; D011836:Radiation Tolerance; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism; D019030:Receptors, Vitronectin / Q000378:metabolism
D039302:Integrin alphaVbeta3; D017468:Receptors, Fibroblast Growth Factor; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5; D016222:Fibroblast Growth Factor 2